Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Genitourinary
06:41

Dana-Farber Cancer Institute

No Role to Continue ICI Beyond Progression: CONTACT-03 & TiNivo-2 Phase 3 Results for mRCC

FEATURING Bradley McGregor
  • 346 views
  • October 3, 2024
  • 4
06:24

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial

FEATURING Bradley McGregor
  • 64 views
  • October 1, 2024
11:59

Dana-Farber Cancer Institute

Outcomes in High-Risk Post-Cystectomy MIBC With Persistent Negative ctDNA: Analysis From the IMvigor011 Study

FEATURING Joaquim Bellmunt
  • 134 views
  • August 29, 2024
  • 2
28:34

Dana-Farber Cancer Institute

Prostate Cancer Highlights From ESMO 2023

FEATURING Michael Serzan, Mary-Ellen Taplin
  • 239 views
  • December 11, 2023
  • 2
20:40

Dana-Farber Cancer Institute

Kidney Cancer Highlights From ESMO 2023

FEATURING Wenxin Xu, Toni Choueiri
  • 176 views
  • December 11, 2023
02:33

Dana-Farber Cancer Institute

ESMO 2023 Summary: "Refining Risk Stratification in Patients Undergoing RT and Long-Term ADT for High-Risk/Locally Advanced Prostate Cancer"

FEATURING Praful Ravi
  • 96 views
  • November 9, 2023
01:53

ecancer

ESMO 2023 Insights: "Results From Phase 2 LITESPARK-003 Study - Belzutifan+Cabozantinib Combination for Advanced ccRCC"

FEATURING Toni Choueiri
  • 80 views
  • October 25, 2023
02:23

ecancer

ESMO 2023 Insights: "Comparing Belzutifan With Everolimus in Pretreated Advanced Clear Cell RCC - Results From LITESPARK-005 Study"

FEATURING Toni Choueiri
  • 72 views
  • October 25, 2023
25:33

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 2023

FEATURING Jacob Berchuck, Atish Choudhury
  • 1,162 views
  • May 16, 2023
  • 8
04:50

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU 2023

FEATURING Alok Tewari
  • 88 views
  • May 16, 2023
  • 1
20:18

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023

FEATURING Wenxin Xu, Toni Choueiri
  • 262 views
  • May 16, 2023
19:48

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023

FEATURING Charlene Mantia, Joaquim Bellmunt
  • 137 views
  • May 16, 2023
  • 1
15:35

Dana-Farber Cancer Institute

Updates on the Management of Non-Clear Cell RCC

FEATURING Bradley McGregor
  • 222 views
  • May 2, 2023
  • 1
14:36

OncoAlert

RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clear-Cell RCC

FEATURING Toni Choueiri
  • 409 views
  • March 1, 2023
14:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Prostate Cancer

FEATURING Anthony D'Amico
  • 154 views
  • February 22, 2023
51

Dana-Farber Cancer Institute

Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis

FEATURING Atish Choudhury
  • 21 views
  • July 28, 2022
09:06

Dana-Farber Cancer Institute

CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Subgroup Analysis

FEATURING Atish Choudhury
  • 169 views
  • July 28, 2022
03:13

Dana-Farber Cancer Institute

Outcomes of1L Ipi-Nivo & Subsequent Therapy in mRCC: Results From the International Database Consortium

FEATURING Andrew Schmidt
  • 18 views
  • June 11, 2021
25:49

Dana-Farber Cancer Institute

Beyond "The Big Three" Lynch Syndrome-Linked Cancers: What Are the Risk Factors? Should We Screen for the "Other" Cancers?

FEATURING Matthew Yurgelun
  • 7 views
  • January 28, 2021
13:19

Dana-Farber Cancer Institute

2020 ESMO IPATential150 Trial Data on mCRPC: Does Ipatasertib Combined With Abiraterone Acetate + Prednisone Lead to a Significantly Superior rPFS and Antitumor Activity in PTEN Loss Disease?

FEATURING Christopher Sweeney
  • 292 views
  • October 29, 2020
  • 1
26:17

Dana-Farber Cancer Institute

Current and Emerging Agents to Treat Advanced Bladder Cancer

FEATURING Guru Sonpavde
  • 823 views
  • March 5, 2019
  • 3
10:29

Dana-Farber Cancer Institute

Study of Atezolizumab and Bevacizumab in Variant Histology RCC: Data Support Evolving role of IO, PD-L1 Could be an IO Biomarker

FEATURING Bradley McGregor
  • 547 views
  • February 26, 2020
  • 1
08:37

Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update: Review of FDA's Approval of the First Targeted Agent for Metastatic Urothelial Carcinoma - FGFRi Erdafitinib

FEATURING Guru Sonpavde
  • 1,661 views
  • June 24, 2019
  • 5
16:32

Dana-Farber Cancer Institute

DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Analysis of Ongoing Clinical Trials - Enfortumab Vedotin Monotherapy, Gemcitabine/Cisplatin+Bevacizumab, Maintenance Pembrolizumab, and Coexpression Extrapolation (COXEN)

FEATURING Guru Sonpavde
  • 363 views
  • June 24, 2019
  • 1